REFERENCES
- Adler L.P., Crowe J.P., al-Kaisi N.K., et al. Evaluation of Breast Masses and Axillary Lymph Nodes with [F-18] 2-Deoxy-2-Fluoro-d-Glucose PET. Radiology 1993; 187: 743–750
- Avril N., Dose J., Janicke F., et al. Metabolic Characterization of Breast Tumors with Positron Emission Tomography Using F-18 Fluorodeoxyglucose. J. Clin. Oncol. 1996; 14: 1848–1857
- Hawkins R.A., Hoh C., Glaspy J., et al. Positron Emission Tomography Scanning in Cancer. Cancer Investig. 1994; 12: 74–87
- Crowe J.P.J., Adler L.P., Shenk R.R., et al. Positron Emission Tomography and Breast Masses: Comparison with Clinical Mammographic, and Pathological Findings. Ann. Surg. Oncol. 1994; 1: 132–140
- Boerner A.R., Weckesser M., Herzog H., et al. Optimal Scan Time for Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer. Eur. J. Nucl. Med. 1999; 26: 226–230
- Bender H., Kirst J., Palmedo H., et al. Value of 18 Fluoro-deoxyglucose Positron Emission Tomography in the Staging of Recurrent Breast Carcinoma. Anticancer Res. 1997; 17: 1687–1692
- Casey M.J., Gupta N.C., Muths C.K. Experience with Positron Emission Tomography (PET) in Patients with Ovarian Cancer. Gynecol. Oncol. 1994; 53: 331–338
- Schiepers C., Penninckx F., De Vadder N., et al. Contribution of PET in the Diagnosis of Recurrent Colorectal Cancer: Comparison with Conventional Imaging. Eur. J. Surg. Oncol. 1995; 21: 517–522
- Lapela M., Grenman R., Kurki T., et al. Head and Neck Cancer: Detection of Recurrence with PET and 2-18F-Fluoro-2-Deoxy-d-Glucose. Radiology 1995; 197: 205–211
- Steinert H.C., Boni R.A.H., Buck A., et al. Malignant Melanoma: Staging with Whole-Body Positron Emission Tomography and 2-18F-Fluoro-2-Deoxy-d-Glucose. Radiology 1995; 195: 705–709
- Inoue T., Kim E.E., Komaki R., et al. Detecting Recurrent or Residual Lung Cancer with FDG-PET. J. Nucl. Med. 1995; 36: 788–793
- Moon D.H., Maddahi J., Silverman D.H., et al. Accuracy of Whole-Body Fluorine-18-FDG PET for the Detection of Recurrent or Metastatic Breast Carcinoma. J. Nucl. Med. 1998; 39: 431–435
- Hathaway P.B., Mankoff D.A., Maravilla K.R. Value of Combined FDG PET and MR Imaging in the Evaluation of Suspected Recurrent Local–Regional Breast Cancer: Preliminary Experience. Radiology 1999; 210: 807–814
- Bakheet S.M., Saleem M., Powe J., et al. F-18 Fluorodeoxyglucose Chest Uptake in Lung Inflammation and Infection. Clin. Nucl. Med. 2000; 25: 273–278
- Shreve P.D., Anzai Y., Wahl R.L. Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants. Radiographics 1999; 19: 61–77
- Tse N.Y., Hoh K., Hawkins R.A., et al. The Application of Positron Emission Tomography with Fluorodeoxyglucose to the Evaluation of Breast Disease. Ann. Surg. 1992; 216: 27–34
- Wahl R.L., Cody R.L., Hutchins G.D., et al. Primary and Metastatic Breast Carcinoma: Initial Clinical Evaluation with PET with the Radiolabeled Glucose Analogue 2-F-18-Fluoro-2-Deoxy-d-Glucose. Radiology 1991; 179: 765–770
- Jones H.A., Clarck R.J., Rhodes C.G., et al. In Vivo Measurement of Neutrophils Activity in Experimental Lung Inflammation. Am. J. Respir. Crit. Care Med. 1994; 149: 1635–1639
- Schuster D.P. The Evaluation of Lung Infection with PET. Semin. Nucl. Med. 1998; 28: 341–351
- Meyer M., Gast T., Raja S., et al. Increased F-18 FDG Accumulation in an Acute Fracture. Clin. Nucl. Med. 1994; 19: 13–14